A guide to selection and appropriate use of macrolides in skin infections

American Journal of Clinical Dermatology

Volumn 4, Issue 6, 2003, Pages 389-397

  Parsad, Davinder ^a   Pandhi, Roma ^a   Dogra, Sunil ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; ANTICOAGULANT AGENT; AZITHROMYCIN; CARBAMAZEPINE; CEFACLOR; CISAPRIDE; CLARITHROMYCIN; CLOXACILLIN; CLOZAPINE; CYCLOSPORIN; DICLOXACILLIN; DIGOXIN; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; MACROLIDE; METHYLPREDNISOLONE; MIDAZOLAM; MINOCYCLINE; PENICILLIN G; ROXITHROMYCIN; TERFENADINE; TETRACYCLINE; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GRAM POSITIVE BACTERIUM; HUMAN; HYPERSENSITIVITY REACTION; LIVER TOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SKIN FLORA; SKIN INFECTION; TASTE DISORDER;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; SKIN DISEASES, BACTERIAL;

EID: 0037973366     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304060-00003     Document Type: Review

References (75)

1. Shah E. Erythromycin. Pediatr Rev 1998; 19: 140-1
2. Charles L, Segreti J. Choosing the fight macrolide antibiotic: a guide to selection Drugs 1997; 53: 349-57
3. Cornish P, Tailor SAN. The new macrolides: azithromycin and clarithromycin. Metro Toronto Hospitals Drug Information Service 1994; 13: 20-41
4. Ballow CH, Amsden GW. Azithromycin: the first azalide anti-biotic. Ann Pharmacother 1992; 26: 1253-61
5. Brisson-Noel A, Trieu-Cuot P, Courvalin P. Mechanism of action of spiramycin and other macrolides. J Antimicrob Ther 1998; 22 Suppl. B: 13-23
6. Champney WS, Burdine R. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 2141-4
7. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin and roxithromycin. Ann Pharmacother 1992; 26: 46-55
8. Sturgill MG, Rapp RP, Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favourable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992; 26: 1099-108
9. Mandell LA. The renaissance of the macrolides: new and changing roles in infections diseases. Can J Infect Dis 1993; 4 Suppl. A: 1A-4A
10. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides. Drugs 2000; 61: 443-98
11. Ednie LM, Spangler SK, Jacobs MR, et al. Susceptibilities of 228 penicillin and erythromycin-susceptible and resistant pneumococci to RU-64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob Agents Chemother 1997; 41: 1033-6
12. Hardy DJ, Hensey DM, Beyer JM, et al. Comparative in vitro activities of new 14, 15 and 16 membered macrolides. Antimicrob Agents Chemother 1988; 32: 1710-9
13. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infection. Drugs 1996; 51: 483-505
14. Kitiz MD, Goldstein FW, Miegi M, et al. In vitro activity of azithromycin against various gram negative bacilli and anaerobic bacteria. J Antimicrob Chemother 1990; 25: 15-8
15. Gelber RH, Sui P, Tsang M, et al. Activities of various macrolide antibiotics against M. leprae infection in mice. Antimicrob Agents Chemother 1991; 35: 760-3
16. Naik S, Ruck R. In vitro activities of several new macrolides antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989; 33: 1614-6
17. Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis 1993; 17: 7-20
18. Fernandez-Martin J, Leport C, Morlat P, et al. Pyrimetamine-clarithromycin combination for therapy of acute toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991; 35: 2049-52
19. Wynn RF, Leen CLS, Brettle RP. Azithromycin for cerebral toxoplasmosis in AIDS. Lancet 1993; 341: 243-4
20. Ji B, Jamet P, Perani EG, et al. Powerful activities of clarithromycin and minocycline against M leprae in lepromatous leprosy. J Infect Dis 1993; 168: 188-90
21. Leclereq R, Courvalin P. Bacterial resistance to macrolide antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267-72
22. Sepala H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326: 292-7
23. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39: 577-85
24. Roberts MC, Sutcliffe J, Courvalin P, et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999; 43: 2823-30
25. Cocito C, Di Giambattista M, Nyssen E, et al. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997; 39: 7-13
26. Westh H, Hougaard D, Vuust J, et al. Prevalence of erm gene classes in erythromycin-resistant S. aureus strains isolated between 1959 and 1988. Antimicrob Agents Chemother 1995; 39: 369-73
27. Duval J. Evolution and epidemiology of MLS resistance. J Antimicrob Chemother 1985; 16 Suppl. A: 137-49
28. Thabut A, Meyram M, Huerre M. Evolution and presentation of Staphylococcus aureus sensitivity to MLS in hospital (1975-83). J Antimicrob Chemother 1985; 16 Suppl. A: 20-32
29. Bass JW, Weisse ME, Plymer MR, et al. Decline of erythromycin resistance in group A streptococci. Arch Pediatr Adolesc Med 1994; 148: 67-71
30. Welby PL, Keller DS, Cromien JL, et al. Resistance to penicillin and non-beta-lactum antibiotics of Streptococcus at children's hospital. Pediatr Infect Dis J 1994; 13 (4): 281-7
31. Coonan KM, Kaplan EL. In vitro susceptibility of group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 1994; 13: 630-5
32. Ohana N, Keness J, Verner E, et al. Skin-isolated, community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin. J Am Acad Dermatol 1989; 21: 544-6
33. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139: 4-8
34. Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989; 33: 1419-22
35. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl. A: 73-82
36. Trembley D, Mignot A, Couraud L, et al. Concentrations of roxithromycin in lung tissue after repeat dosing. Br J Clin Pract 1988; 44 Suppl. 55: 64-6
37. Girard AE, Girard A, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987; 31: 1948-54
38. Bonnet M, Van der Auwere P. In vitro and in vivo intraleukocytic ex vivo leukocyte chemiluminescence, Antimicrob Agents Chemother 1992; 36: 1302-9
39. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34: 1056-60
40. MeConnell SA, Amsdem GW. Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. Pharmacotherapy 1999; 19: 404-15
41. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77 Suppl. 6: 7-11
42. Derrick Jr CW, Reilly KM, Stallworth JR. Erythromycin in the treatment of streptococcal infections. Pediatr Infect Dis 1986; 5: 172-6
43. Sharma PK, Yadav TP, Gautam RK, et al. Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000; 42: 241-4
44. Akers WA, Allen AM, Burnett JW, et al. Systemic antibiotics for treatment of can vulgaris: efficacy and safety. Arch Dermatol 1975; 111: 1630
45. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991; 19: 433-45
46. Lassus A. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990; 25 Suppl. A: 115-21
47. Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis 1991; 10: 880-4
48. Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. J Antimicrob Chemother 1996; 37 Suppl. C: 125-31
49. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993 Jun; 31 Suppl. E: 111-7
50. Strle F, Preac-Mursic V, Cimperman J, et al. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 1993; 21: 83-8
51. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxiciliin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-91
52. Gruber F, Grubisic-Greblo H, Kastelan M, et al. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa. J Chemother 1998; 10: 469-73
53. Parsad D, Pandhi R, Nagpal R, et al. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001 Jan; 28 (1): 1-4
54. Northcutt VJ, Craft JC, Pichotta P. Safety and efficacy of clarithromycin compared to erythromycin in the treatment of bacterial skin or skin structure infection [abstract]. In. Program and Abstracts of the 30th Interscience Conference on Antimicrobial agents and Chemotherapy; 1990, Atlanta
55. Parish LC and the Clarithromycin Study Group. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int J Dermatol 1993; 32: 528-32
56. Franzblau SG, Hastings RC. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother 1988; 32: 1758-62
57. Brown BA, Wallace Jr RJ, Onyi GO. Activities of four macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-4
58. Barry AL, Jones RN, Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268:TE-03I), erythromycin, roxithromycin and clindamycin. Antimicrob Agents Chemother 1988; 32: 752-4
59. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with AIDS. Am Rev Respir Dis 1991; 144: 564-9
60. Wallace Jr RJ, Tanner D, Sattler FR, et al. Clinical trial of clarithromycin for cutaneous infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119: 482-6
61. Vemulapalli RK, Cantey JR, Steed LL, et al. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001; 43: 163-8
62. Deiriennic M, Escande JP. Dirithromycin in the treatment of skin and skin structure infections. J Antimicrob Chemother 1993; 31 Suppl. C: 159-68
63. Epstein ME, Groton MA, Sadick NS. Antimicrobial agents for dermatologists. II. J Am Acad Dermatol 1997; 37: 365-81
64. Agache P, Amblard P, Moulin G, et al. Roxithromycin in skin and soft tissue infections. J Antimicrob Chemother 1987; 20 Suppl. B: 153-6
65. Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127: 155-9
66. Pilot MA, Qin XY. Macrolide and gastrointestinal motility. J Antimicrob Chemother 1988; 22 Suppl. B: 201-6
67. Washington II JA, Wilson WR. Erythromycin: a microbial and clinical prospective after 30 year of clinical use. Mayo Clin Proc 1985; 60: 271-8
68. Eichenwald HF. Adverse reaction to erythromycin. Pediatr Infect Dis J 1986; 5: 147-50
69. Periti P, Mazzei T, Mini E, et al. Adverse effects of of macrolide antibacterials. Drug Saf 1993; 9: 346-64
70. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79
71. Descotes J, Andre P, Evreux JC. Pharmacokinetic drug interactions with macrolide antibiotics J Antimicrob Chemother 1985; 15: 659-64
72. Rodin SM, Johnson BE. Pharmacokinetic drug interactions with digoxin antibiotics. Clin Pharmacokinet 1988; 15: 227-44
73. Periti P, Mazzei T, Mini E. Pharmacokinetic drug interactions with macrolide. Clin Pharmacokinet 1992; 23: 106-31
74. von Rosensteil NA, Adam D. Macrolide antibacterial: drug interaction of clinical significance. Drug Saf 1995; 13: 105-22
75. Nahata M. Drug interaction with azithromycin and macrolides: an overview. J Antimicrob Chemother 1996; 37 Suppl. C: 133-42